Compare

Cagrilintide vs IGF-1 LR3

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Cagrilintide

1559 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 53% · Mixed 28% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-38
Appetite control
5
Energy
-34
Mood
-17
Focus
-127

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-122
GI discomfort
-95
Dizziness
-69
Fatigue
-21
Nausea
-128

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05 to ≥ 5 mg (open-ended top bucket)

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
12
0.4–0.6 mg
18
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
4
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing43stacking21side effects19cagrilintide17

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 25 days · Based on 343 repeat reporters

IGF-1 LR3

764 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 68% · Mixed 16% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-117
Focus
-162
Sleep quality
-145
Lean mass
-166
Joint comfort
-101

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-21
Nausea
-83
Water retention
0
Appetite loss
10
Injection site reaction
-101

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
2
50–100
13
100–200
22
200–400
11
400–600
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing48stacking31side effects34igf-1 lr322

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 168 repeat reporters

Sources (8)

Published sources linked on the Cagrilintide and IGF-1 LR3 wiki pages.

  1. PubMed

    Cagrilintide, a long-acting amylin analogue, for the treatment of obesity

    Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022

    Source
    Wiki study page →
  2. ClinicalTrials.gov

    Cagrilintide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  3. PubMed

    Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

    D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024

    Source
    Wiki study page →
  4. PubMed

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  5. PubMed

    Insulin-like growth factor-I and its binding proteins in sport and exercise medicine

    Baxter RC. Endocr Rev. 2011

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    IGF-1 LR3 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

    Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025

    Source
    Wiki study page →
  8. PubMed

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

    Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025

    Source
    Wiki study page →